Published in PLoS One on April 29, 2011
ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta (2012) 1.58
Oncogenic activation of ERG: A predominant mechanism in prostate cancer. J Carcinog (2011) 1.13
Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Res (2013) 1.11
Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals. Mol Cancer Ther (2013) 1.10
Metadherin mediates lipopolysaccharide-induced migration and invasion of breast cancer cells. PLoS One (2011) 1.04
Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget (2012) 1.04
Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer. Am J Transl Res (2013) 0.96
Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines. Nucleic Acids Res (2012) 0.95
A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein. Mol Cancer Ther (2014) 0.94
The oncogene ERG: a key factor in prostate cancer. Oncogene (2015) 0.93
A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model. PLoS One (2014) 0.85
Structures of the Ets Protein DNA-binding Domains of Transcription Factors Etv1, Etv4, Etv5, and Fev: DETERMINANTS OF DNA BINDING AND REDOX REGULATION BY DISULFIDE BOND FORMATION. J Biol Chem (2015) 0.83
Regulation of CXCR4-mediated invasion by DARPP-32 in gastric cancer cells. Mol Cancer Res (2012) 0.83
Targeted therapies for advanced Ewing sarcoma family of tumors. Cancer Treat Rev (2015) 0.81
Recent advances in the structural molecular biology of Ets transcription factors: interactions, interfaces and inhibition. Biochem Soc Trans (2014) 0.80
ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents. Oncotarget (2015) 0.78
Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov (2016) 0.78
YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model. Oncotarget (2015) 0.78
Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma. Sarcoma (2011) 0.78
Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells. Cancer Cell Int (2014) 0.76
Potential for targeted therapy in prostate cancers with ERG abnormalities. Asian J Androl (2011) 0.75
The RNA helicase A in malignant transformation. Oncotarget (2016) 0.75
The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer (2017) 0.75
Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer. Cancers (Basel) (2017) 0.75
Modeling the Mechanism of GR/c-Jun/Erg Crosstalk in Apoptosis of Acute Lymphoblastic Leukemia. Front Physiol (2012) 0.75
Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. Oncotarget (2017) 0.75
The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis. Cancer Lett (2017) 0.75
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene (2007) 5.79
Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J (2010) 4.78
ETS transcription factors and their emerging roles in human cancer. Eur J Cancer (2005) 3.55
Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther (2007) 2.97
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene (2008) 2.94
Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer (2006) 2.69
Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol (2007) 2.68
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol (2007) 2.48
A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med (2009) 2.17
Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci (2006) 1.96
Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res (2009) 1.76
Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res (2008) 1.68
The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. Biochim Biophys Acta (2006) 1.60
GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem (2009) 1.56
Real-time impedance assay to follow the invasive activities of metastatic cells in culture. Biotechniques (2002) 1.51
Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res (2006) 1.32
LNCaP prostatic adenocarcinoma cells derived from low and high passage numbers display divergent responses not only to androgens but also to retinoids. J Steroid Biochem Mol Biol (1997) 1.27
The prostate transglutaminase (TGase-4, TGaseP) regulates the interaction of prostate cancer and vascular endothelial cells, a potential role for the ROCK pathway. Microvasc Res (2008) 0.96
Macrophage migration inhibitory factor (MIF) promotes fibroblast migration in scratch-wounded monolayers in vitro. FEBS Lett (2007) 0.94
Id2 protein is selectively upregulated by UVB in primary, but not in immortalized human keratinocytes and inhibits differentiation. Oncogene (2005) 0.90
Thalidomide increases human keratinocyte migration and proliferation. J Invest Dermatol (1999) 0.86
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol (2004) 2.92
A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med (2009) 2.17
Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest (2010) 1.73
High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One (2010) 1.54
VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells. Cancer Biol Ther (2010) 1.49
AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther (2009) 1.48
Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBFbeta. Chem Biol (2007) 1.44
Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel blockers. Clin Prostate Cancer (2003) 1.44
Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. Clin Cancer Res (2010) 1.36
Voltage-sensitive ion channels and cancer. Cancer Metastasis Rev (2006) 1.34
Predicting new indications for approved drugs using a proteochemometric method. J Med Chem (2012) 1.29
Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism. Mol Cell Biol (2008) 1.27
The role of IGF-1R in pediatric malignancies. Oncologist (2009) 1.27
Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA. J Biol Chem (2012) 1.25
Sazetidine-A, a selective alpha4beta2 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats. J Pharmacol Exp Ther (2009) 1.24
Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent. Future Oncol (2005) 1.22
Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats. Psychopharmacology (Berl) (2010) 1.20
STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc Natl Acad Sci U S A (2013) 1.20
Activation of the canonical Wnt pathway during genital keratinocyte transformation: a model for cervical cancer progression. Cancer Res (2005) 1.18
Recombinant EWS-FLI1 oncoprotein activates transcription. Biochemistry (2004) 1.16
Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men. Int J Oncol (2009) 1.13
Design, synthesis and evaluation of novel hydroxyamides as orally available anticonvulsants. Bioorg Med Chem (2004) 1.13
Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res (2005) 1.11
Structure-based discovery of a boronic acid bioisostere of combretastatin A-4. Chem Biol (2005) 1.07
Voltage-gated sodium channel blockers as cytostatic inhibitors of the androgen-independent prostate cancer cell line PC-3. Mol Cancer Ther (2003) 1.06
Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer (2008) 1.04
Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget (2012) 1.04
Identification and characterization of a new tubulin-binding tetrasubstituted brominated pyrrole. Mol Pharmacol (2007) 1.04
PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis. Oncogene (2005) 1.03
Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia. Pediatr Blood Cancer (2010) 1.02
Asymmetric synthesis of 2,3-dihydro-2-arylquinazolin-4-ones: methodology and application to a potent fluorescent tubulin inhibitor with anticancer activity. J Med Chem (2008) 1.02
Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats. Psychopharmacology (Berl) (2011) 1.02
Forced expression of the H11 heat shock protein can be regulated by DNA methylation and trigger apoptosis in human cells. J Biol Chem (2003) 1.00
Pediatric malignancies provide unique cancer therapy targets. Curr Opin Pediatr (2005) 1.00
Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: implications for tumor biology and therapy. J Biol Chem (2011) 1.00
Wnt/Frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer (2004) 1.00
PTPL1: a large phosphatase with a split personality. Cancer Metastasis Rev (2008) 1.00
Assessing the effects of chronic sazetidine-A delivery on nicotine self-administration in both male and female rats. Psychopharmacology (Berl) (2012) 1.00
A real-time electrical impedance based technique to measure invasion of endothelial cell monolayer by cancer cells. J Vis Exp (2011) 0.99
Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: a report from the Children's Oncology Group. Cancer (2011) 0.99
Secreted Frizzled-related protein potentiation versus inhibition of Wnt3a/β-catenin signaling. Cell Signal (2013) 0.99
Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage. Mol Cancer Ther (2013) 0.98
Synthesis and evaluation of hermitamides A and B as human voltage-gated sodium channel blockers. Bioorg Med Chem (2011) 0.97
Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue. Mol Cancer Ther (2008) 0.96
DIM (3,3'-diindolylmethane) confers protection against ionizing radiation by a unique mechanism. Proc Natl Acad Sci U S A (2013) 0.96
Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorg Med Chem (2007) 0.95
Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells. Oncotarget (2013) 0.94
Small molecule inducers of angiogenesis for tissue engineering. Tissue Eng (2006) 0.92
Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting. Clin Cancer Res (2014) 0.92
A pharmacophore derived phenytoin analogue with increased affinity for slow inactivated sodium channels exhibits a desired anticonvulsant profile. Neuropharmacology (2006) 0.92
Beta-catenin accelerates human papilloma virus type-16 mediated cervical carcinogenesis in transgenic mice. PLoS One (2011) 0.91
Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells. Bioorg Med Chem (2011) 0.90
Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI. Cell Cycle (2012) 0.90
Ligand-based design and synthesis of novel sodium channel blockers from a combined phenytoin-lidocaine pharmacophore. Bioorg Med Chem (2008) 0.89
IGF-1R targeted treatment of sarcoma. Lancet Oncol (2009) 0.89
Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects. Oncotarget (2013) 0.89
Chemistry and pharmacological studies of 3-alkoxy-2,5-disubstituted-pyridinyl compounds as novel selective α4β2 nicotinic acetylcholine receptor ligands that reduce alcohol intake in rats. J Med Chem (2013) 0.88
Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma. Oncotarget (2014) 0.88
Fluorescent epigenetic small molecule induces expression of the tumor suppressor ras-association domain family 1A and inhibits human prostate xenograft. J Med Chem (2010) 0.87
Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors. Cell Cycle (2011) 0.87
Factor VII deficiency and developmental abnormalities in a patient with partial monosomy of 13q and trisomy of 16p: case report and review of the literature. BMC Med Genet (2006) 0.86
VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. Cancer Biol Ther (2011) 0.86
Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6. Bioorg Med Chem (2003) 0.86
Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. Oncotarget (2014) 0.85
Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor. Mol Cancer Ther (2011) 0.85
Design, synthesis and discovery of picomolar selective α4β2 nicotinic acetylcholine receptor ligands. J Med Chem (2013) 0.84
Expansion of microvascular networks in vivo by phthalimide neovascular factor 1 (PNF1). Biomaterials (2008) 0.84
Discovery of diphenyl amine based sodium channel blockers, effective against hNav1.2. Bioorg Med Chem (2006) 0.84
Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo. Cancer Res (2006) 0.84
Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer. Bioorg Med Chem (2004) 0.84
Mechanistic exploration of phthalimide neovascular factor 1 using network analysis tools. Tissue Eng (2007) 0.83
Novel carbazole inhibits phospho-STAT3 through induction of protein-tyrosine phosphatase PTPN6. J Med Chem (2014) 0.83
A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent. Bioorg Med Chem (2009) 0.83
Synthesis of C-glycoside analogues of beta-galactosamine-(1-->4)-3-O-methyl-D-chiro-inositol and assay as activator of protein phosphatases PDHP and PP2Calpha. Bioorg Med Chem (2010) 0.83
Thalidomide and analogues: current proposed mechanisms and therapeutic usage. Clin Prostate Cancer (2004) 0.82
Acetylation Increases EWS-FLI1 DNA Binding and Transcriptional Activity. Front Oncol (2012) 0.82
Facile synthesis of an azido-labeled thalidomide analogue. Org Lett (2003) 0.82
Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study. Pediatr Blood Cancer (2013) 0.81
Design, synthesis, and development of novel caprolactam anticonvulsants. Bioorg Med Chem (2003) 0.81
Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma. Clin Orthop Relat Res (2014) 0.81
An intrinsically disordered region of the acetyltransferase p300 with similarity to prion-like domains plays a role in aggregation. PLoS One (2012) 0.81
Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin. Eur J Pharm Sci (2004) 0.81
Novel pathway compendium analysis elucidates mechanism of pro-angiogenic synthetic small molecule. Bioinformatics (2008) 0.81
Human genome search in celiac disease: mutated gliadin T-cell-like epitope in two human proteins promotes T-cell activation. J Mol Biol (2002) 0.80